Cerus Posts Record $233.8M 2025 Revenue, Q4 IFC Demand Jumps 50%
Chief Operating Officer Vivek Jayaraman said Cerus finished 2025 with record product revenue of $233.8 million, a 16% increase, and saw IFC demand rise over 50% in Q4 with kit sales growing to 70%. The next-generation INT200 device earned CE mark and U.S. PMA submission is on track for mid-2026.
1. Record 2025 Financial Results
Cerus ended 2025 with $233.8 million in total revenue, up 16% year-over-year, driven by a 14% rise in product revenue that exceeded guidance. Foreign exchange contributed a roughly 3% benefit in Q4 and 1.6% for the full year, while EMEA product revenue grew 25% ex-FX in Q4.
2. IFC Business Expansion
Customer demand for Intercept Flow Cytometry (IFC) rose over 50% in Q4, boosting IFC revenue by nearly 40% year-over-year. Kit-based sales comprised about 70% of IFC sales, up from 50% a year earlier, and management expects nearly all IFC volume to shift to kits by end-2026.
3. INT200 Rollout and Regulatory Status
The INT200 next-generation LED-based illuminator earned CE mark approval and launched commercially in Europe, receiving positive operational feedback. Cerus has an installed base of 400 INT-100 devices in EMEA and remains on track to submit a U.S. PMA application for INT200 in mid-2026.
4. BCA Agreement and U.S. Market Penetration
A group purchasing agreement with Blood Centers of America, representing roughly 50% of U.S. blood supply, went into effect January 1 and is expected to accelerate platelet adoption. Cerus estimates platelet market share in the mid-60s and sees potential to expand within BCA’s 30% current penetration.